Lsl Pharma Group Inc (LSL.VN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX Venture]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX Venture]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 06-2024 | 03-2024 | 12-2023 | 09-2023 | 06-2023 | |
| Sales | 4,191 | 4,163 | 3,458 | 2,512 | 2,034 |
| Cost of Goods | 2,655 | 3,017 | 3,359 | 2,045 | 1,342 |
| Gross Profit | 1,536 | 1,146 | 99 | 467 | 692 |
| Operating Expenses | 1,661 | 967 | -185 | 803 | 3,404 |
| Operating Income | -125 | 179 | 285 | -336 | -2,712 |
| Interest Expense | 382 | 446 | 591 | 357 | 389 |
| Other Income | -9 | -13 | -170 | -69 | 0 |
| Pre-tax Income | -516 | -280 | -476 | -762 | -3,101 |
| Net Income Continuous | -516 | -280 | -476 | -762 | -3,101 |
| Net Income | $-516 | $-280 | $-476 | $-762 | $-3,101 |
| EPS Basic Total Ops | 0.00 | 0.00 | -0.01 | -0.01 | -0.04 |
| EPS Basic Continuous Ops | 0.00 | 0.00 | -0.01 | -0.01 | -0.04 |
| EPS Diluted Total Ops | 0.00 | 0.00 | -0.01 | -0.01 | -0.04 |
| EPS Diluted Continuous Ops | 0.00 | 0.00 | -0.01 | -0.01 | -0.04 |
| EBITDA(a) | $212 | $500 | $359 | $-58 | $-2,423 |